Pulmatrix (NASDAQ:PULM) Stock Price Passes Below 50-Day Moving Average – Here’s Why

Posted by ABMN Staff on Feb 17th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) shares crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.71 and traded as low as $2.44. Pulmatrix shares last traded at $2.43, with a volume of 5,040 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pulmatrix currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on PULM

Pulmatrix Stock Performance

The firm has a 50 day moving average price of $2.71 and a 200 day moving average price of $4.07.

Hedge Funds Weigh In On Pulmatrix

A number of hedge funds and other institutional investors have recently modified their holdings of the business. DRW Securities LLC purchased a new position in Pulmatrix during the fourth quarter valued at approximately $46,000. Dimensional Fund Advisors LP purchased a new stake in Pulmatrix during the third quarter worth $52,000. Finally, SBI Securities Co. Ltd. boosted its position in Pulmatrix by 15.7% during the 2nd quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 8,208 shares in the last quarter. 11.84% of the stock is currently owned by institutional investors.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).